










# ROBUST PIPELINE OF SWITCH-CONTROL KINASE INHIBITORS

		PRE-CLINICAL	PHASE 1	PHASE 1B/2	PHASE 3	REGULATORY SUBMISSION	APPROVED	COMMERCIAL RIGHTS	
 (ripretinib) 50mg tablets Broad-Spectrum Inhibitor of KIT and PDGFRA	GIST ≥4 <sup>th</sup> Line (INVICTUS Study)						 <sup>1</sup>	 <sup>2</sup>  <sup>2</sup> + Global Approvals <sup>3</sup>	
	GIST 2 <sup>nd</sup> Line (INTRIGUE Study)								
	GIST Post-Imatinib in Combination with Binimetinib			Phase 1 Initiation Planned for 4Q 2021 <sup>4</sup>					
<b>Vimseltinib (DCC-3014)</b> Selective Inhibitor of CSF1R	Tenosynovial Giant Cell Tumor (TGCT) (MOTION Study)				Phase 1/2 ongoing	Phase 3 Initiation Planned for 4Q 2021 <sup>4</sup>			
<b>Rebastinib</b> Selective Inhibitor of TIE2	Platinum-Resistant Ovarian Cancer (PROC) in Combination with Paclitaxel					Phase 3 Initiation Planned for 2022 <sup>4,5</sup>			
<b>DCC-3116</b> Selective Inhibitor of ULK	RAS/RAF Mutant Cancers In Combination with Trametinib								
<b>Additional Programs</b>	Undisclosed								



**Notes:** CSF1R=colony-stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFRA=platelet-derived growth factor receptor α; RAS=rat sarcoma gene; TIE2=TEK tyrosine kinase; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like kinase; (1) European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of QINLOCK (ripretinib) for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib; (2) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (3) QINLOCK is approved for 4th line GIST in the United States, Australia, Canada, China, Hong Kong, Switzerland, and Taiwan; (4) Represent planned 2021-2022 milestones; (5) Subject to discussions with health authorities.